MediciNova Releases Phase Ib Clinical Study Results for MN-221

MediciNova has reported results from its Phase Ib clinical trial of MN-221 for the treatment of preterm labor.

The Phase Ib clinical trial enrolled 10 healthy, pregnant volunteers who were not in labor. The volunteers received a single-dose intravenous infusion regimen of MN-221, consisting of two consecutive rounds of a 15-minute priming and a 105-minute maintenance infusion to deliver 294 micrograms of MN-221 over the course of four hours, MediciNova said.

The primary objectives of this clinical trial were to determine the pharmacokinetics, safety and tolerability of this infusion regimen of MN-221 in pregnant women, the company added.

According to MediciNova, no significant safety concerns were identified in the trial.